Welcome to our dedicated page for Black Diamond Therapeutics SEC filings (Ticker: BDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Black Diamond is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, with a lead focus on silevertinib/BDTX-1535 in EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
Through this page, users can review current and historical filings such as Forms 10-K and 10-Q, which describe the company’s research and development activities, clinical trial programs in NSCLC and GBM, and risk factors associated with developing MasterKey therapies. Form 8-K filings, including those announcing quarterly financial results and corporate updates, provide additional detail on cash position, operating expenses, and material agreements like the global licensing arrangement with Servier for BDTX-4933.
Investors can also reference registration statements, proxy materials, and, where applicable, insider transaction reports on Form 4 to better understand equity ownership and changes in holdings by officers, directors, and significant shareholders. These documents collectively outline how Black Diamond funds and prioritizes its development of brain-penetrant EGFR inhibitors and mutation-focused small molecules.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify disclosures related to clinical milestones, partnerships, cash runway, and other factors relevant to BDTX. Real-time updates from EDGAR ensure that new Black Diamond Therapeutics filings appear promptly, while AI-generated overviews make complex oncology and biotechnology disclosures more accessible.
Vestal Point Capital and Ryan Wilder filed an amended Schedule 13G reporting passive ownership in Black Diamond Therapeutics, Inc. common stock. They report beneficial ownership of 870,000 shares, representing 1.5% of the company’s common stock outstanding as of October 30, 2025.
The shares are held through a fund and managed account advised by Vestal Point Capital, with shared voting and dispositive power over all 870,000 shares. The filers state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Black Diamond Therapeutics.
Black Diamond Therapeutics, Inc. reports an option grant to senior management. Officer Erika Jones, who serves as Senior Vice President, Finance and Corporate Controller, was granted a stock option to purchase 200,000 shares of common stock at an exercise price of $2.57 per share on January 21, 2026.
According to the vesting terms, 25% of the shares subject to this option will vest and become exercisable on January 21, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on her continued service with the company. Following this grant, she holds 200,000 derivative securities (stock options) directly.
Black Diamond Therapeutics granted its Chief Operating Officer and General Counsel, Brent Hatzis-Schoch, a stock option for 250,000 shares of common stock on January 21, 2026. The option has an exercise price of $2.57 per share and is scheduled to expire on January 20, 2036.
According to the vesting terms, 25% of the option will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on his continued service. After this grant, he beneficially owns 250,000 derivative securities directly.
Black Diamond Therapeutics, Inc. reported that its Chief Scientific Officer, Elizabeth Buck, received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $2.57 per share and were granted on January 21, 2026, with an expiration date of January 20, 2036. According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, conditioned on her continued service. Following this grant, she holds 250,000 derivative securities directly.
Black Diamond Therapeutics, Inc. reported that its chief medical officer, Sergey Yurasov, received a grant of stock options covering 250,000 shares of common stock on January 21, 2026. The options have an exercise price of $2.57 per share and were awarded at no cost for the options themselves.
According to the vesting terms, 25% of the option shares will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments after that date, contingent on Dr. Yurasov’s continued service. Following this grant, he holds stock options for 250,000 derivative securities directly.
Black Diamond Therapeutics President and CEO Mark A. Velleca reported a new stock option grant. On January 21, 2026, he was awarded a stock option to buy 600,000 shares of Black Diamond Therapeutics common stock at an exercise price of $2.57 per share. According to the vesting terms, 25% of the shares under this option will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, conditioned on his continued service with the company. Following this grant, he beneficially owns 600,000 derivative securities in the form of this option, held directly.
Black Diamond Therapeutics reported that a non-employee director received 5,208 shares of common stock as compensation for annual board service.
The shares were issued on December 12, 2025 under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, after the director elected to take stock instead of cash fees.
The award was valued at $2.76 per share, based on the closing market price on December 11, 2025. Following this grant, the director beneficially owns 86,649 shares directly and has additional indirect interests in shares held by investment funds affiliated with New Enterprise Associates, while disclaiming beneficial ownership of portions in which there is no pecuniary interest.
Black Diamond Therapeutics reported that one of its non-employee directors acquired 4,665 shares of the company’s common stock on December 12, 2025, as reflected in a Form 4 insider trading report.
The shares were issued under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, after the director elected to receive stock instead of cash for annual board service. The value was based on the $2.76 closing market price on December 11, 2025, and the director now beneficially owns 31,027 shares held directly.
Black Diamond Therapeutics filed a shelf registration on Form S-3 to offer, from time to time, up to $500,000,000 of common stock, preferred stock, debt securities, warrants, and/or units. The filing also includes a sales agreement prospectus for an at-the-market program of up to $150,000,000 in common stock under an Open Market Sale AgreementSM with Jefferies LLC, which is part of the $500,000,000 shelf.
Under Rule 415(a)(6), the filing carries forward $400,005,680.55 of unsold securities from a prior shelf (File No. 333-268341); that prior offering will be deemed terminated upon effectiveness of this registration. The company’s common stock trades on Nasdaq as BDTX, and 56,943,413 shares were outstanding as of September 30, 2025. Net proceeds from any future sales are intended for general corporate purposes, including R&D, clinical development, working capital, and capital expenditures.